Two executives have launched a new Silicon Valley firm, MDisrupt, designed to assess the medical claims made by health tech startups to help investors to separate the wheat from chaff and guide startups seeking to commercialize products.
It plans to bring its idiopathic pulmonary fibrosis small molecule to the clinic in the next two years.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Minerva Surgical's ablation procedure to reduce menstruation can, ostensibly, be completed in less than four minutes.
The company has a "unique" approach to treating Alzheimer's, CEO Arnon Rosenthal says - taking an immunotherapy approach to neurodegenerative disease.
A spinoff of Sofinnova Ventures, Healthquest Partners focuses more on diagnostics, medical devices and health IT startups.
PaxVax will use the funding to pay off its debts, as well as launch a cholera vaccien called Vaxchora.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Audentes Therapeutics, a San Francisco-based gene therapy startup, just raised $65 million to advance three candidates to the clinic that treat X-linked myotubular myopathy, Pompe disease and a rare form of tachycardia called CPVT.
The Altura device offers a way to graft to the renal artery in a less invasive manner that's meant to be simpler and more intuitive.
The Fogarty Institute just launched three new startups, all in women's health. The Silicon Valley-based nonprofit helps medical device upstarts get off their feet and avoid the "valley of death."
Bay Area startup SutroVax just raised $22 million for work in developing conjugate vaccines - and likely improving upon existing inoculations for pneumococcal conditions.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Bay Area startup Channel Medsystems' technology freezes the uterine lining to prevent excess menstrual building. It just raised $23.9 million for this device, which can be used in less than three minutes.
Expanding the oral targeted therapy offerings for GI diseases like IBD, Protagonist Therapeutics plans to go up against the blockbusters like Humira and Remicade
Mousera, the brainchild of Proteus alum Timothy Robertson, is building a data-heavy platform to accelerate preclinical drug discovery and development.
The three West Coast venture firms are teaming up to build a stealth new startup called Nexcida Therapeutics. They are developing therapeutics for infectious disease, but haven't disclosed anything else.
Advanced Cell Diagnostics just raised a $22 million Series C to enter the clinical and research diagnostics space - with aims to be used as a precision medicine tool. It profiles single gene expression in situ, studying the targeted molecular structure of each cell in a sample - and can detect every gene in the human transcriptome, the startup says.